Filing Flows › Krystal Biotech (KRYS) › Q3 2025
Krystal Biotech (KRYS) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 3, 2025
Krystal Biotech (KRYS) reported revenue of $97.8M for the third quarter 2025 (Q3 2025), +17% from a year earlier and +2% from the quarter before. Operating margin was 42.3%, net earnings $79.4M (81.2% of revenue).
Krystal Biotech, Q3 2025: revenue $97.8M (+17% year over year), operating margin 42.3%, net earnings $79.4M, operating cash flow $39.7M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $97.8M | +2% | +17% |
| Operating profit | $41.4M | +5% | +84% |
| Net earnings | $79.4M | +107% | +192% |
| Operating cash flow | $39.7M | -25% | -33% |
| Free cash flow | $38.0M | -25% | -34% |
What changed
Revenue was $97.8M in Q3 2025, up 17% year over year and up 2% from the previous quarter.
Operating profit was $41.4M, a 42.3% margin (up 15.5 points year over year). Of the extra revenue versus a year earlier, 135% reached operating profit, above the 27% margin then. Total costs fell 8% while revenue rose 17%. The fastest-growing cost line was SG&A (+31%). Net earnings were $79.4M, up 192% year over year. The effective tax rate was -65.5%.
Operating cash flow was $39.7M (down 33% year over year), 50% of net earnings. Non-cash charges added back $1.4M of depreciation and $13.2M of share-based compensation. Working capital and other items used $54.3M. Capital expenditures of $1.7M left free cash flow of $38.0M.
Questions
What was Krystal Biotech's revenue in the third quarter 2025?
Krystal Biotech (KRYS) reported revenue of $97.8M for the third quarter 2025 (Q3 2025), +17% from a year earlier and +2% from the quarter before.
Was Krystal Biotech profitable in the third quarter 2025?
Operating profit was $41.4M (42.3% of revenue) and net earnings $79.4M.
Source: Krystal Biotech 10-Q on SEC EDGAR.